Hikma Eyes Another Hybrid Injectable With Arecor

Second Agreement Using 505(b)(2) Pathway

 
• By Dean Rudge

London-listed Hikma has signed a second partnership agreement with Arecor, proposing to co-develop a 505(b)(2) hybrid injectable product for the US market.

Handshake
Hikma and Arecor have shaken hands on another hybrid injectable co-development agreement • Source: Shutterstock

More from Deals

More from Business